<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01470053</url>
  </required_header>
  <id_info>
    <org_study_id>HL_NSFX_301</org_study_id>
    <nct_id>NCT01470053</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind Phase Ⅲ Study of Mometasone Furoate/Azelastine Hydrochloride Combination Group and Mometasone Furoate and Azelastine Hydrochloride Group 4 Weeks After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Perennial Allergic Rhinitis Patient.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate of efficacy and safety of mometasone furoate plus
      azelastine HCl in patients with perennial allergic rhinitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in rTNSS(reflective Total Nasal Symptom Score)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from baseline in AM rTNSS(AM reflective Total Nasal Symptom Score)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in PM rTNSS(PM reflective Total Nasal Symptom Score)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in iTNSS(instantaneous Total Nasal Symptom Score)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in AM iTNSS(AM instantaneous Total Nasal Symptom Score)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in PM iTNSS(PM instantaneous Total Nasal Symptom Score)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">347</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>mometasone furoate + azelastin HCl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>opaque suspension, four times each naris per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mometasone furoate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>opaque suspension, four times each naris per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>azelastine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lucidus colorless liquid, two times each naris per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mometasone furoate plus azelastine HCl</intervention_name>
    <arm_group_label>mometasone furoate + azelastin HCl</arm_group_label>
    <other_name>Nasaflex Nasal Spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mometasone furoate</intervention_name>
    <arm_group_label>mometasone furoate</arm_group_label>
    <other_name>NASONEX NASAL SPRAY</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azelastine HCl</intervention_name>
    <arm_group_label>azelastine HCl</arm_group_label>
    <other_name>AZEPTIN NASAL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 12 years of age

          -  Medical history of perennial allergic rhinitis for at least two years

          -  Moderate ro severe nasal symptom (during placebo run-in period AM rTNSS or PM rTNSS≥8)

          -  Positive skin prick test result within the previous 12 months

        Exclusion Criteria:

          -  patients with active asthma that required therapy with inhaled or oral corticosteroids
             or long-term β-agonist

          -  patients with severe rhinostenosis, severely deviated nasal septum or local infection
             on the nasal mucous membrane

          -  patients with herpes zoster, glaucoma or cataract

          -  patients with history of operation or damage on nasal cavity or ocular region

          -  patients with drug-induced rhinitis

          -  patients with history of respiratory infection which requires antibiotic therapy
             within the previous 14 days

          -  Patients with lung disease including COPD

          -  Patients with history of immunotherapy or ongoing immunotherapy

          -  patients administered with super potent or potent corticosteroid

          -  patients administered with intra-muscular or intra-articular steroid within the
             previous 3 months

          -  patients administered with subcutaneous omalizumab within the previous 5 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Gi Min, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2011</study_first_submitted>
  <study_first_submitted_qc>November 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2011</study_first_posted>
  <last_update_submitted>August 26, 2013</last_update_submitted>
  <last_update_submitted_qc>August 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mometasone furoate</keyword>
  <keyword>azelastine HCl</keyword>
  <keyword>perennial allergic rhinitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Azelastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

